Overlapping Vitamin A Intervention Programs: Should We Be Concerned with Excessive Intakes?

Georg Lietz

Population Health Sciences Institute, Human Nutrition Research Centre, Newcastle University, Newcastle upon Tyne, United Kingdom

Vitamin A Intervention Programs and Their Effectiveness

Because ~2.3% of all global deaths among children below the age of 5 y are attributable to vitamin A deficiency (VAD) annually (1), and provision of additional vitamin A (VA) reduces young child mortality by an average of 23%–30% (2, 3), programs have been initiated to reduce VAD through application of biannual high-dose VA supplements, micronutrient powder distribution, food fortification, or biofortification (4). Efforts to reduce VAD through these programs have resulted in an impressive 10% prevalence reduction worldwide from 39% in 1991 to 29% in 2013, yet VAD remains a global public health problem, especially in sub-Saharan Africa and South Asia (5). Where VAD is persisting, a combination of VA interventions will be required to achieve sustainable VA adequacy. However, overlapping VA interventions in the same population group have the potential of overexposing individuals at the high end of the intake distribution curve (6–8). This is particularly problematic if these interventions are not well coordinated between the different public and private sector entities that support these programs.

The article in this issue of The Journal of Nutrition by Sowa et al. (9) aimed to test the effect of VA program overlap by simulating the exposure of Zambian children to provitamin A biofortified foods and preformed VA food fortification using an animal model. Although it is not surprising that combined consumption of preformed VA with biofortified maize increased liver VA stores more effectively than either approach alone, their statement that this overlap resulted in “excessive” liver VA stores, despite downregulation of provitamin A conversion, potentially increases the concern about the safety of overlapping VA interventions.

Contribution of Provitamin A Carotenoids to Excessive VA Stores?

Assuming that downregulation of provitamin A conversion through higher intakes of preformed VA is not protecting against excessive liver VA accumulation, the results by Sowa et al. (9) raise 2 important questions: 1) can provitamin A carotenoids contribute to excessive liver VA stores when to date these nutrients have been regarded as “safe” owing to the downregulation of cleavage enzymes during high preformed VA intake (10, 11); and 2) do we need to change the definition of the tolerable upper intake level (UL) for VA by including the contributions of provitamin A carotenoids?

Our current understanding of intestinal provitamin A carotenoid uptake and conversion assumes a saturable and protein-mediated uptake through a variety of intestinal transporters including Scavenger receptor class B type I (SCARB1), followed by the conversion into retinal via β-carotene 15, 15′-oxygenase (BCO1) (11, 12). This process is regulated by the intestine-specific homeobox transcription factor (ISX), which enhances the expression of SCARB1 and BCO1 during vitamin A intake (10, 11); and reduces their expression when sufficient dietary preformed VA is consumed (10, 11). Results from Sowa et al. (9) confirmed that increased intake of preformed retinol reduces the intestinal expression levels of SCARB1 and BCO1 during VAD, but did not confirm any involvement of ISX in gerbils. The lack of involvement of ISX in their study could be due to a mismatch of the amplicon sequence or a low qPCR amplicon efficiency, both of which were not tested. However, they did show that liver provitamin A carotenoid concentrations were higher in gerbils that were fed carotenoids and preformed VA than in those that only received provitamin A carotenoids, confirming a downregulation of provitamin A bioconversion by preformed VA. Contrarily, although Sowa et al. (9) confirm a downregulation of provitamin A bioconversion, they claim that constant exposure to both provitamin A and preformed VA would induce “excessive” VA liver stores compared with animals that were only fed similar amounts of preformed VA. In other words, the authors claim that the negative feedback mechanism exerted by preformed VA on provitamin A bioconversion does not prevent a potentially dangerous accumulation of VA in the liver. If this observation were true,
the current definition of the UL for dietary VA would need to be revised, because it currently only applies to preformed retinol (13). Importantly, because the authors did not test a range of VA doses to establish hypervitaminosis or VA toxicity, this observation relies on using a liver VA cutoff of 1 μmol/g for “hypervitaminosis A.”

What Are the Adequate Cutoff Values for “Hypervitaminosis A” or VA Toxicity?

It is important to note that the evidence for setting the cutoff for “hypervitaminosis A” is limited (14). The Biomarkers of Nutrition for Development Vitamin A Expert Panel agreed to set the cutoff for liver VA toxicity at 10 μmol/g liver, but used the term “hypervitaminosis A” for liver VA concentrations between 1 and 10 μmol/g liver until more data exist with regard to adverse effects (14). The use of these terminologies is potentially confusing, particularly as the older literature uses “hypervitaminosis A” for describing VA toxicity with clear pathophysiological indicators such as perisinusoidal fibrosis, hyperplasia, and hypertrophy of stellate cells (15–17). Most importantly, the lowest intake amount to cause pathophysiological confirmed chronic VA toxicity [200 μg/kg body weight (16)] is about 4 times higher than the UL for children aged 2–5 y of age [~50 μg/kg body weight; based on the UL of 600 and 900 μg/d and a mean body weight of 12 and 18 kg for 2- and 5-y-old children, respectively (14, 18)]. “Hypervitaminosis A,” defined as liver VA concentrations >1 μmol/g liver (19, 20), has been reported to occur in >59% (21) or >64% (22) of children with VA intake amounts below the UL of 900 μg/d for this age group. Because the UL is defined as the “highest daily intake still considered to be safe for almost all healthy individuals in a specified group” (7), it raises the question of whether the liver VA cutoff for “hypervitaminosis A” is set too low. Thus, liver VA concentrations >1 μmol/g liver may simply describe “high” rather than “excessive” VA stores with no adverse health effects. Although Sowa et al. (9) refer to an observation of liver abnormality and bone fragility in rats at daily VA intake amounts below the UL for human adults [3000 μg/d (14)], the dose consumed in the cited animal study [2727 μg · rat⁻¹ · d⁻¹ (23); equivalent to 8536 μg/kg body weight] was 43 times higher than the lowest observed intake amount to cause chronic VA toxicity (200 μg/kg body weight) in humans (16). Furthermore, the same study also reported 7 times higher liver VA and 20 times higher serum retinyl ester concentrations in the high VA intake group than in the control group (23). It is important to remember that the current cutoff value for “hypervitaminosis A” (>1.05 μmol/g liver) was proposed by Olson in 1984 based on the hypothetical relation between liver and plasma concentrations of VA; i.e., that “once the liver storage mechanism for VA is largely saturated plasma levels of VA shall sharply rise” (19). Indeed, the theoretical cutoff for VA toxicity in liver of >1.05 μmol/g was subsequently accompanied by a cutoff value for plasma total VA concentration of >3.5 μmol/L to include circulating retinyl esters (20). Thus, according to Olson (20), “hypervitaminosis A” occurs when both criteria are confirmed, as described in rats suffering from liver abnormality and bone fragility (23). Consequently, owing to a lack of clear pathophysiological findings indicative of VA toxicity in animals or humans with liver concentrations ~1 μmol/g liver, there is no sufficient evidence at this point in time to associate the current cutoff value with any adverse health effects. Furthermore, there is an urgent need to redefine the use of the terminology “hypervitaminosis A,” particularly in light of the older publications that use the same description for VA toxicity.

In conclusion, more data are needed to accurately determine cutoff values for biomarkers for assessing excessive VA status to enable a comprehensive evaluation of the safety of current ongoing and planned future VA interventions and programs. The study by Sowa et al. (9) raises an important question as to whether provitamin A carotenoid intake needs to be more carefully evaluated. However, because of the current uncertainty regarding the liver VA cutoff value for “hypervitaminosis A,” more research is urgently needed to establish a well-defined cutoff value for evaluating the safety of VA interventions and programs. A liver VA cutoff value could be applied to human populations by using the retinol isotope dilution method to estimate liver VA concentration indirectly in field settings.

Acknowledgments

I thank Anthony Osxley for commenting on the manuscript. The sole author was responsible for all aspects of this manuscript.

References

1. Black RE, Victora CG, Walker SP, Bhatta ZA, Christian P, de Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 2013;382:427–51.
2. Fawzi WW, Chalmers TC, Herrera MG, Mosteller F. Vitamin A supplementation and child mortality: a meta-analysis. JAMA 1993;269:898–903.
3. Mayo-Wilson E, Imdad A, Herzer K, Yakoob MY, Bhutta ZA. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. BMJ 2011;343:d5094.
4. Klemm RD, Palmer AC, Greig A, Engle-Stone R, Dalmiya N. A changing landscape for vitamin A programs: implications for optimal intervention packages, program monitoring, and safety. Food Nutr Bull 2010;31:75–86.
5. Stevens GA, Bennett JE, Hennocq Q, Lu Y, De-Regil LM, Rogers L, Danaei G, Li G, White RA, Flaxman SR, et al. Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys. Lancet Glob Health 2015;3:e528–36.
6. Brown KH, Engle-Stone R, Kajin J, Retting E, Vosti SA. Use of optimization modeling for selecting national micronutrient intervention strategies: an example based on potential programs for control of vitamin A deficiency in Cameroon. Food Nutr Bull 2015;36:S141–8.
7. Bruins MJ, Kupka R, Zimmermann MB, Lietz G, Engle-Stone R, Kraemer K. Maximizing the benefits and minimizing the risks of intervention programs to address micronutrient malnutrition: symposium report. Matern Child Nutr 2016;12:940–8.
8. Engle-Stone R, Vosti SA, Luo H, Kajin J, Tarini A, Adams KP, French C, Brown KH. Weighing the risks of high intakes of selected micronutrients compared with the risks of deficiencies. Ann N Y Acad Sci 2019;1446:81–101.
9. Sowa M, Mouroa L, Shefief J, Kaeppf M, Simongs G, Grahn M, Davis CR, von Lietz J, Simon PW, Pixley KV, et al. Overlapping vitamin A interventions with provitamin A carotenoids and preformed vitamin A cause excessive liver retinol stores in male Mongolian gerbils. J Nutr 2020;150(11):2912–23.
10. Lietz G, Lange J, Rumbach G. Molecular and dietary regulation of β,β-carotene 15,15-monoxygenase 1 (BCMO1). Arch Biochem Biophys 2010;502:8–16.
11. von Lietz J. Provitamin A metabolism and functions in mammalian biology. Am J Clin Nutr 2012;96:1234s–44s.
12. Borel P. Genetic variations involved in interindividual variability in carotenoid status. Mol Nutr Food Res 2012;56:228–40.
13. Institute of Medicine. Using the tolerable upper intake level for nutrient assessment of groups. Washington (DC): National Academy Press; 2000.
14. Tanumihardjo SA, Russell RM, Stephensen CB, Gannon BM, Craft NE, Haskell MJ, Lietz G, Schulze K, Ratten DJ. Biomarkers of Nutrition for Development (BOND)—vitamin A review. J Nutr 2016;146:1816s–48s.
15. Ellis JK, Russell RM, Makrauer FL, Schaefer EJ. Increased risk for vitamin A toxicity in severe hypertriglyceridemia. Ann Intern Med 1986;105:877–9.
16. Myhre AM, Carlsen MH, Bøhn SK, Wold HL, Laake P, Blomhoff R. Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. Am J Clin Nutr 2003;78:1152–9.
17. Zafrani ES, Bernuau D, Feldmann G. Peliosis-like ultrastructural changes of the hepatic sinusoids in human chronic hypervitaminosis A: report of three cases. Hum Pathol 1984;15:1166–70.
18. WHO. WHO Child Growth Standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization; 2006.
19. Olson JA. Serum levels of vitamin A and carotenoids as reflectors of nutritional status. J Natl Cancer Inst 1984;73:1439–44.
20. Olson JA. Vitamin A. Brown ML, editor. In: Present knowledge in nutrition. 6th ed, chapter 11. Washington (DC): International Life Sciences Institute-Nutrition Foundation; 1990, 96–107.
21. Gannon B, Kaliwile C, Arscott SA, Schmaelzle S, Chileshe J, Kalungwana N, Mosonda M, Pixley K, Masi G, Tanumihardjo SA. Biofortified orange maize is as efficacious as a vitamin A supplement in Zambian children even in the presence of high liver reserves of vitamin A: a community-based, randomized placebo-controlled trial. Am J Clin Nutr 2014;100:1541–50.
22. van Stuijvenberg ME, Dhansay MA, Nel J, Suri D, Grahn M, Davis CR, Tanumihardjo SA. South African preschool children habitually consuming sheep liver and exposed to vitamin A supplementation and fortification have hypervitaminotic A liver stores: a cohort study. Am J Clin Nutr 2019;101:90–101.
23. Johansson S, Lind PM, Häkansson H, Oxlund H, Orberg J, Melhus H. Subclinical hypervitaminosis A causes fragile bones in rats. Bone 2002;31:685–9.